|1.||Smith, Peter G: 13 articles (01/2015 - 05/2010)|
|2.||Sun, Yi: 12 articles (12/2014 - 01/2011)|
|3.||Jia, Lijun: 11 articles (10/2015 - 06/2011)|
|4.||Jeong, Lak Shin: 7 articles (04/2015 - 07/2012)|
|5.||Milhollen, Michael A: 7 articles (10/2013 - 01/2010)|
|6.||Chu, Yiwei: 5 articles (10/2015 - 07/2012)|
|7.||Wei, Dongping: 5 articles (04/2015 - 01/2012)|
|8.||Zhao, Yongchao: 5 articles (12/2014 - 05/2012)|
|9.||Narayanan, Usha: 5 articles (01/2013 - 09/2010)|
|10.||Li, Chunjie: 4 articles (10/2015 - 01/2014)|
10/01/2015 - "To assess the therapeutic efficacy of neddylation inhibition in GBM, cell proliferation in vitro and tumor growth in vivo were determined upon neddylation inhibition by MLN4924, an investigational NEDD8-activating enzyme inhibitor. "
10/01/2012 - "MLN4924 is a first-in-class inhibitor of the proximal regulator of the NEDD8 system (NEDD8-activating enzyme, NAE) that has entered Phase-I trials for cancer therapy and has established that significant therapeutic benefit can be achieved by antagonizing NEDD8-mediated protein degradation. "
07/01/2012 - "Recently, the anticancer small molecule MLN4924 currently in phase I trials was determined to be an inhibitor of NAE that blocks cullin neddylation and inactivates CRL, triggering an accumulation of CRL substrates that trigger cell-cycle arrest, apoptosis, and senescence in cancer cells. "
03/20/2012 - "MLN4924 is an investigational small-molecule inhibitor of NEDD8-activating enzyme (NAE) in clinical trials for the treatment of cancer. "
01/01/2012 - "Our study reveals an uncharacterized mechanism of MLN4924 action and provides the proof-of-concept evidence for strategic drug combination of MLN4924 with an autophagy inhibitor for maximal killing of tumor cells via enhancing apoptosis."
|2.||Liver Neoplasms (Liver Cancer)
07/01/2012 - "Together, our findings support the clinical investigation of MLN4924 for liver cancer treatment and provide a preclinical proof-of-concept for combination therapy with an autophagy inhibitor to enhance therapeutic efficacy."
04/20/2015 - "We reported previously that inhibition of neddylation pathway with specific NAE inhibitor MLN4924, suppressed the malignant phenotypes of liver cancer. "
07/01/2012 - "Here, we report that MLN4924 also triggers autophagy in response to CRL inactivation and that this effect is important for the ability of MLN4924 to suppress the outgrowth of liver cancer cells in vitro and in vivo. "
07/01/2012 - "The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth."
07/01/2012 - "In a xenograft model of human liver cancer, MLN4924 was well-tolerated and displayed a significant antitumor effect characterized by CRL inactivation and induction of autophagy and apoptosis in liver cancer cells. "
|3.||Stomach Neoplasms (Stomach Cancer)
01/01/2015 - "In summary, our findings unveiled a protective role of P27 by maintaining mitochondrial membrane permeability in MLN4924-treated gastric cancer cells, and therefore highlighted the potential combination of MLN4924 with P27 inhibition to improve its therapeutic efficacy. "
01/01/2015 - "In this study, MLN4924 induced significant growth inhibition of gastric cancer cells in a dose-dependent manner, along with the simultaneous accumulation of P27 and cell cycle abnormalities such as G2/M arrest. "
01/01/2015 - "MLN4924, an anti-tumor agent, which suppresses the SCF complex by inhibiting Cullin1 neddylation, emerges as a promising tool to elucidate its functions in gastric cancer cells. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
10/11/2013 - "Taken together, these results indicate that CRL4(CDT2) is a potential drug target in ovarian cancers and that MLN4924 may be an effective anticancer agent for targeted ovarian cancer therapy. "
10/11/2013 - "MLN4924-induced DNA damage and apoptosis were partially rescued by Cdt1 depletion, suggesting that CRL4(CDT2) repression and CDT1 accumulation were key biochemical events contributing to the genotoxic effects of MLN4924 in ovarian cancer cells. "
10/11/2013 - "Depletion of CRL4 components Roc1/2, Cul4a, and DDB1 had inhibitory effects on ovarian cancer cells similar to MLN4924 treatment, which suggested that CRL4 inhibition contributed to the chemotherapeutic effect of MLN4924 in ovarian cancers. "
10/11/2013 - "In addition, MLN4924 sensitized ovarian cancer cells to other chemotherapeutic drug treatments. "
10/01/2013 - "Overall, single-agent MLN4924 exhibited moderate activity in ovarian cancer cell lines. "
07/28/2015 - "MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies."
07/28/2015 - "In this study, we investigated the anti-tumor effect of MLN4924 in human urothelial carcinoma (UC) in vitro and in vivo by using three human UC cell lines of various grading (T24, NTUB1 and RT4). "
01/01/2015 - "The combination of cisplatin and MLN4924 exerted synergistic cytotoxicity on two high-grade bladder urothelial carcinoma cell lines, NTUB1 and T24 (combination index <1). "
01/01/2015 - "MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma."
01/01/2015 - "This study investigated the anti-tumor effect and underlying mechanisms of the combination of cisplatin and the NEDD8-activating enzyme inhibitor MLN4924 in human bladder urothelial carcinoma. "
|4.||Proteins (Proteins, Gene)
|6.||DNA (Deoxyribonucleic Acid)
|9.||Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)